Diese Veranstaltung hat bereits stattgefunden


Fr12 The MacTel Project: An update on Macular Telangiectasia Type 2 - what\'s new?

Symposium of the DOG 2020 Online
online, Deutschland
Veranstaltungsnummer: 34062
Zertifizierung: beantragt
Gebühren ab: gebührenfrei
verfügbare Plätze: unbegrenzt
Sprache: Deutsch

 Zum Kalender hinzufügen
  • Datum
    09.10.2020, 17:30 - 18:15
    DOG - Deutsche Ophthalmologische Gesellschaft e.V.
    This symposium is about Macular Telangiectasia Type II (MacTel). They belong to the class of rare macular diseases. Nevertheless, MacTel is a highly interesting topic due to its unique research environment that yields new insights on the anatomy, pathophysiology, functional testing and imaging of the macula.


    Teilnehmer max.

    Gebühren ab
    110,00 €
    This symposium is part of the DOG congress 2020 (9.-11.2020). A ticket for the 9th of October costs 110€ (International Society of Ocular Trauma (ISOT)-Day included). The attandance for the total congress costs 250€ for members and 120€ for non-members.

    Ärzte/-innen in Weiterbildung

    Teilnehmer max.

    Gebühren ab
    110,00 €
    This symposium is part of the DOG congress 2020 (9.-11.2020). A ticket for the 9th of October costs 110€ (International Society of Ocular Trauma (ISOT)-Day included). The attandance for the total congress costs 250€ for members and 120€ for non-members.


    Teilnehmer max.

    Gebühren ab
    The full congress is free for students and PhD students.
  • Over the past thirteen years, intensive research of an international and interdisciplinary consortium of researchers has led to significant advances in our understanding of the pathogenesis, natural history, prognostic markers and development of novel therapeutic approaches for MacTel. A recently published paper in the New England Journal of Medicine (NEJM) showed that elevated systemic deoxysphingolipid levels and low systemic serine levels are risk factors for MacTel and peripheral neuropathies.
    An international natural history and registry study helped characterizing the natural course and determining genetic risk factors of this disease. A clinical phase III intervention study with the Renexus implant, which delivers CNTF into the vitreous, promises a first treatment approach.
    As with other chronic and slow progressing diseases, one of the challenges in clinical trials for MacTel is to determine functional endpoints that reflect patients’ everyday impairments as well as disease progression. MacTel patients with advanced morphological changes and severe functional impairment often present with good central visual acuity. This represents a particular problem in clinical trials as the success of therapy cannot be adequately monitored. Thus, the establishment of alternative functional measurements such as reading speed or microperimetry plays an important role for the success of future clinical trials.
    Anatomical structural investigations of the macular region are another important pillar of MacTel research. In addition to histological examinations of donor tissue, novel imaging methods such as OCT angiography offer a deeper insight into the pathophysiology of the disease. These studies revealed that the neurodegenerative component in MacTel precedes the observed vascular changes emphasizing the chronic neurodegenerative character of the disease. However, the presence of secondary vascular changes may still have an influence on treatment success. Early detection of the disease as well as early therapeutic intervention is therefore of great importance. Multimodal (autofluorescence, blue light reflectance) and novel imaging techniques (FLIO) improve the possibilities of early detection.

    17:30 – 17:43

    Fr12-01 - The MacTel Project: Genetics + Metabolomics

    Referent/in: Martin Friedlander, La Jolla, United States

    17:43 – 17:51

    Fr12-02 - Imaging and early diagnosis in MacTel

    Referent/in: Simone Tzaridis, La Jolla, United States

    Macular telangiectasia type 2 (MacTel) is a bilateral, slowly-progressive retinal disease that is characterized by both neurodegenerative and vascular changes. Multimodal imaging allows to detect and monitor disease-associated changes and helps to diagnose the disease at early stages. Very early alterations include a depletion of macular pigment, increased signals on fundus autofluorescence and fluorescein angiography imaging, an asymmetric configuration of the foveal pit, and prolonged lifetimes on Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO).

    17:51 – 17:59

    Fr12-03 - Functional Testing in MacTel

    Referent/in: Kristina Heß, Bonn

    Patients with Macular Telangiectasia Type 2 (MacTel) exhibit retinal alterations which usually arise in the temporal parafovea.  While central visual acuity can be preserved, patients may suffer from severe impairment of reading acuity, contrast sensitivity, dark adaptation and stereoscopic vision. Fundus-controlled perimetry allows visualizing and monitoring the size and position of (para)central scotoma and has therefore been shown to be an adequate functional outcome in existing and future clinical trials.

    17:59 – 18:07

    Fr12-04 - OCT-Angiography and anatomy of the macula in MacTel

    Referent/in: Frederic Gunnemann, Münster

    Optical coherence tomography (OCT-A) allows visualization and quantification of vessel abnormalities in macular teleangiectasia (MacTel) type 2.
    Pathological vascular alterations in MacTel are initially most obvious in the deep capillary vascular network and progressively also occur in different other retinal layers in advanced disease stages.
    OCT-A provides a valuable multimodal imaging addition to monitor pathological and progressive vascular changes in patients with MacTel. 

    18:07 – 18:15

    Fr12-05 - Clinical trials in MacTel with a translational view on CNTF

    Referent/in: Felicitas Bucher, Freiburg

    There is currently no validated treatment option for macular telangiectasia type 2. This talk provides an overview of ongoing clinical trials on MacTel with an emphasis on the phase 3 clinical trial evaluating Renexus, an implant using encapsulated cell therapy (ECT) to continuously deliver ciliary neurotrophic factor (CNTF) to the vitreous and a translational view on CNTF.
  • This symposium is virtual. Saal von Graefe

    Congress, Meeting & Event Management AG
    Landsberger Straße 155
    DE - 80687 München
    Tel.: +49 (0)89 548 234 35
    Tel.: +49 (0)89 548 234 0
    Fax: +49 (0)89 548 234 43
    Fax: +49 (0)89 548 234 44


    Organisator / Vorsitzender: Felicitas Bucher, Freiburg
    Vorsitzende/r: Daniel Pauleikhoff, Münster
    Vorsitzende/r: Frank G. Holz, Bonn

    Please contact the organizer for further information.